ABSTRACT
INTRODUCTION Endoplasmic Reticulum (ER) -a protein quality control machinery of the cell
The endoplasmic reticulum (ER) is an organelle that has essential roles in multiple cellular processes that are required for cell survival and normal cellular functions. These processes include intracellular calcium homeostasis, protein secretion and lipid biosynthesis (1) . The lumen of the ER constitutes a unique cellular environment (2) . For instance, the highest concentrations of calcium within the cell are found in the ER owing to active transport by Ca 2+ -ATPases. In addition, because of its role in protein folding and transport in the secretory pathway, the ER is also rich in calcium-dependent altered glycosylation, nutrient deprivation, oxidative stress, DNA damage or energy perturbation/ fluctuations, can interrupt the protein folding process and result in ER stress. To ensure the fidelity of protein folding and to handle the accumulation of unfolded or misfolded proteins, ER has evolved a group of signal transduction pathways; the unfolded protein response (UPR) signaling pathways that alter transcriptional and translational programs (4, 5) . The basic UPR pathways in mammalian cells consist of signaling cascades initiated by the three primary ER-localized protein stress sensors: IRE1D (Inositol requiring 1 alpha), PERK (double-strand RNAactivated protein kinase-like ER kinase) and ATF6 (Activating transcription factor 6).
When cells encounter ER stress, an immediate response will be the activation of ER stress sensor PERK through its homo dimerisation and auto-phosphorylation (6) . Activated PERK phosphorylate translation initiation factor elf2D, leading to protein translation attenuation that provides a survivor signal, as this can reduce ER workload by preventing newly synthesized proteins from entering into the ER which is saturated by unfolded or misfolded proteins. ER stress is initially relieved by the UPR, mediated by the transcription factor XBP1, but over time, the UPR becomes less effective or desensitized and the deleterious effects of ER stress lead to cell death, mediated by IRE1D. Desensitized UPR might activate other cellular stresses, including activation of mitogenactivated protein kinases (MAPKs), Jun N-terminal kinase (JNK) and nuclear factor-OB (NF-OB). UPR also activates ATF6 that induces expression of genes involved in restoring ER homeostasis as well as autophagy genes. Therefore, the primary role of the UPR is to prevent the cell from ER stress by reducing the amount of proteins translocated into the ER lumen, increasing retro translocation and degradation of ERlocalized proteins, and augmenting the protein-folding capacity of the ER (Fig 1) . However, if the attempt to recover from ER stress fails, the UPR will induce cell death programs to eliminate the stressed cells and might subsequently contribute to disease-states such as diabetes and its complications.
ER stress and diabetes
Several molecular, genetic and biochemical factors cause the loss of metabolic fuel homeostasis in type 2 diabetes. The growing understanding of the core elements of the insulin signalling pathway and its modulators also provides opportunities for the identification of novel drug targets and therapeutic measures. Hotamisligil et al (7) have postulated that obesity may lead to ER stress in metabolically active tissues. Indeed, in both the adipose and liver of mice chronically fed a high-fat diet, PERK and IRE1D phosphorylation and JNK activity were shown significantly increased compared to lean animals (8) . The causality between susceptibility to ER stress and insulin resistance was supported by genetic manipulation of XBP1 in cultured cells and in animals (8) . Regulation of PERK-eIF2D is important for linking ER stress to the control of protein translation. Humans and mice that lack PERK have profound E-cell dysfunction and are severely diabetic (9) , whereas mice with a mutation in the PERK phosphorylation site in eIF2D have fewer E-cells and are diabetic as a result of insulin deficiency (10) . Moreover, feeding of heterozygous Elf2D-mutant mice on a high-fat diet causes distension of the ER lumen in E-cells, a reduction in islet insulin content and diabetes (11) . Global profiling of genes in islet cells in response to ER stress revealed the early degradation of Ins1 and Ins2 mRNAs (12) . Hence, the two major pathological arms of type 2 diabetes-peripheral insulin resistance and defective insulin secretion-are both related to defects in ER function. As shown in (Fig 2) , there exists crosstalk among organs in relation to local and systemic level metabolic alterations and ER stress could be a common denominator in the induction of pathogenesis.
Readers could refer to several reviews that provide evidence for the involvement of ER stress in many disease states including obesity, insulin resistance, and type 2 diabetes (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . In this review, a special attention was given to elucidate how ER stress could explain some of the 'clinical paradoxes' such as secondary sulfonylurea failure, initial worsening of retinopathy during tight glycemic control, insulin resistance induced by protease inhibitors and other clinically relevant observations. ER stress and secondary sulfonylurea failure in type 2 diabetes In many countries, first-or second-line pharmacological treatment of patients with type 2 diabetes consists of sulfonylureas, which stimulate the beta cell to secrete insulin. However, emerging evidence suggests that forcing the beta cell to secrete insulin at a time when it is struggling to cope with the demands of obesity and insulin resistance may accelerate its demise. Despite the widespread use of sulfonylureas, loss of E-cell mass and function has raised concern regarding the use of sulfonylureas for the treatment of type 2 diabetes mellitus because studies have shown that these agents may induce apoptosis in E-cell lines and rodent islets, and sulfonylurea therapy failure is also very common in long-term treated patients (25) . Sustained enhancement of Ca 2+ influx is known to be involved in triggering apoptosis in E-cell under many circumstances, and it has been found that the sustained enhancement of Ca 2+ influx caused by glibenclamide exposure can induce apoptotic cell death in Ecell (26) . In fact, disruption of ER homeostasis, as caused by alterations in ER Ca 2+ concentration, leads to ER stress (27) . Though United Kingdom Prospective Diabetes Study (28) found that the loss of E-cell function was not unique for sulfonylureas but occurred at the same rate of decline in type 2 diabetic patients on metformin or on conventional treatment, it was found recently that in newly diagnosed diabetic patients, Endoplasmic Reticulum Stress in Diabetes sulfonylureas has higher therapeutic failure rate and faster loss of E-cell function than metformin and rosiglitazone (29) . In fact, many studies have reported that chronic use of sulfonylureas could increase the level of proinsulin (misfolded product of ER in E-cells) in plasma of type 2 diabetes, which means that disequilibrium between ER load and folding capacity deteriorated in E-cells (30, 31) . A multicentre, randomised trial also found that early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favorable outcomes on recovery and maintenance of E-cell function compared with treatment with oral hypoglycemic agents (32).
The concept of improving E-cell function by intermittent inhibition of insulin secretion and E-cell rest in individuals with type 2 diabetes was attempted over 30 years ago in a study, where diazoxide was used to reduce the hormonal release (33) . Diazoxide acts via opening of the K + -ATP channels and includes repolarization, inhibited Ca 2+ influx, and cessation of insulin granular exocytosis. Sargsyan et al (34) have demonstrated that attenuation of ER stress as a mechanism of improved E-cell function after diazoxide-induced E-cell rest. Thiazolidinediones (TZDs) have beneficial effects on glucose homeostasis via enhancement of insulin sensitivity and preservation of E-cell function. How TZDs preserve E-cells is uncertain, but it might involve direct effects via both peroxisome proliferator-activated receptor-J dependent andindependent pathways. Lamontagne et al (35) have demonstrated that pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic E-cell at submaximal glucose concentrations. It was suggested that AMPK activation and the metabolic deceleration of the Ecell caused by pioglitazone contribute to its known effects to reduce hyperinsulinemia and preserve E-cell function and act as an antidiabetic agent. Therefore, it has been suggested that forcing the beta cell to hypersecrete insulin may be counterproductive and lead to dysfunction and death via mechanisms that may involve the endoplasmic reticulum and oxidative stress (36, 37) .
Protease inhibitors, insulin resistance and ER stress
Treatment of patients with HIV-protease inhibitors (PIs) has considerably improved the survival and the quality of life of HIV-infected patients, but their use is frequently hindered by an array of metabolic adverse events (38) . Indeed, patients treated with PIs develop lipodystrophy, hyperlipidemia (39) and metabolic disturbances, such as reduction of insulinstimulated glucose uptake (40) . As a result, insulin resistance develops in treated HIV patients leading to type 2 diabetes (41). Parker et al (42) have also demonstrated that ER stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. One of the widely used PI, lopinavir impaired insulin signalling by decreasing the phosphorylation of insulin receptor substrate-1 (IRS-1) and also activated UPR by phosphorylating eIF2D (43) . This study sheds new light on the cellular mechanisms by which HIV-PIs modify insulin signaling in human adipocytes and underline eIF2D phosphorylation as a determinant of PIs-associated metabolic disorders. It is suggested that better understanding of ER stress pathway and its drug targets is an important step to design new drugs devoid of adverse pharmacological effects, therefore minimizing the overall increase of cardiometabolic risk associated with HIV-PIs. In this context, it is important to mention the study by Zha et al (44) in which berberine (a traditional herbal medicine) has been shown to inhibit HIV protease inhibitor-induced inflammatory response by modulating ER Stress. This study provides a new insight into the molecular mechanisms of berberine and shows the potential application of berberine as a complimentary therapeutic agent for HIV infection along with its beneficial cardio-metabolic effects.
ER stress and diabetic retinopathy
The loss of pericytes from the microvessels in diabetic retinas is one of the characteristic pathological changes in the early stage of diabetic retinopathy. Ikesugi et al (45) have shown that the UPR, activated by ER stress, is induced in retinal pericytes by the changes in the glucose concentration and results in the death of pericytes. Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of diabetic retinopathy and its expression is increased in diabetic retinas by the high-glucose, ischemia, and hypoxia, and this leads to the development of neovascularization and/or increased vascular permeability (46). Roybal and colleagues (47) suggested that the ER stress-mediated activating transcriptional factor 4 (ATF4) activation was associated with an over-expression of VEGF. In addition, recent studies indicate that ER stress-induced apoptosis is involved in the death of neurons in the retina under different physiological conditions (48) . A role for ER stress was also implicated in retinal inflammation and diabetic retinopathy (49) . Thus, there is good evidence that the diabetic stress-induced ER stress is involved in vascular abnormalities such as pericyte loss and neovascularization.
Interestingly, Ikesugi et al (45) have demonstrated induction of ER stress in retinal pericytes by glucose deprivation. ER stress leading to apoptosis was observed in this study when pericytes were cultured in glucose concentrations that were reduced from high to low or no glucose. Tight glycemic control can delay the onset and progression of diabetic complications, although trying to maintain tight glycemic control through insulin or hyperglycemic agents often results in acute glucose fluctuations and hypoglycemia, especially in patients with type 1 diabetes (50, 51) . Both chronic glucose fluctuations and hypoglycemia have also been linked to the onset of these complications (52) . Clinically, the establishment of tight glycemic control in patients with retinopathy often results in an initial worsening of their disease (53, 54) . While the mechanism for the initial worsening of retinopathy during tight control is unknown, the study by Ikesugi et al (45) implies that the clinical acceleration of retinopathy as tight control glucose is established might be linked to the increased incidence of rapid glucose swings and hypoglycemia that induces ER stress, a UPR and subsequent apoptosis. Although further work is required to define the exact relationship between the levels of hypoglycemia and ER stress, the current results suggest that controlling ER stress is a newly identified mechanism for controlling the progression of retinopathy as tight glycemic control is clinically initiated.
ER stress and diabetic nephropathy ER stress in renal pathophysiology is a relatively new area of research. Although improved glycemic control and treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ameliorate the progression of diabetic nephropathy to end-stage kidney disease, the mechanisms for such salutary effects have not been clearly identified and are likely myriad. On the basis of rodent experiments and cell culture, ER stress has been proposed as one of the various mechanisms contributing to cellular damage and apoptosis of podocytes and tubular epithelial cells in renal diseases (55) . ER stress associated apoptosis and renal injury contributed to the diabetic nephropathy in rats (56, 57) . Lindenmeyer et al (58) have suggested that in proteinuric diseases, tubular epithelial cells undergo ER stress as an adaptive response and protection but persistence of hyperglycemia and proteinuria may eventually lead to apoptosis. As suggested by Cybulsky (56) , understanding the various aspects of ER stress will provide an opportunity for development of novel therapeutic strategies for proteinuric diseases.
Inter-relationship of ER stress and Autophagy
Autophagy is a highly regulated process involved in the turnover of long-lived proteins and damaged organelles (59) . Autophagy is linked to the ER at many levels (60), and is likely to be a critical component of normal ER function. The ubiquitin-proteasome and autophagy-lysosome systems are the two major degradation routes in eukaryotic cells, and the ER is connected to the proteosome and to autophagy during the degradation of misfolded proteins. Hence, ER stress induced autophagy may have evolved as an alternate mechanism to dispose of misfolded proteins in the ER lumen that cannot be removed through ERAD. A second use for autophagy during ER stress may be the degradation of the damaged ER itself. Given the dynamic nature of the ER, UPRinduced autophagic degradation of the ER could be an integral player in ER plasticity, replenishment, and homeostasis (22) .
Aberrant regulation of autophagy may be detrimental to metabolism. Loss in mice of p62, a protein important for the efficiency of autophagy, results in mature-onset obesity and leptin resistance, as well as metabolic abnormalities (61) . Two studies demonstrated that autophagy is essential for pancreatic islet function and survival and that a lack of autophagy leads to islet degeneration and reduced insulin secretion (62, 63) . There is also evidence for the regulation of autophagy by inflammatory factors such as TNFD that are linked to obesity and type 2 diabetes. Some studies suggest that JNK activation is required for the induction of ER stress-induced autophagy (60) . Although mammalian target of rapamycin (mTOR) is a potential upstream signal that may regulate autophagy in obesity (64) , neither the regulation of autophagy nor its impact on insulin action under conditions of nutrient excess is well understood. Zhou et al (65) have demonstrated that autophagy-mediated insulin receptor down-regulation contributes to endoplasmic reticulum stress-induced insulin resistance. Moreover, attenuated mTOR signaling and enhanced autophagy was reported in adipocytes from obese patients with type 2 diabetes (66). Thus, inflammatory/oxidative pathways that are linked to the UPR and metabolic disease are also linked to autophagy. However, the physiological and pathophysiological consequences of the connection between autophagy and ER stress in metabolic homeostasis and its implications for insulin action still remains an enigma and warrant further in-depth studies.
Antidiabetic drugs and alleviation of ER stress
Natural products are a rich source of modulators of proteins/ enzymes and ligands for nuclear receptors and are promising therapeutic agents in clinical practice. In particular, plants provide an abundant source of biologically active molecules that have played critical roles in pharmacology. Based on a history of traditional therapeutic applications, many of these natural products have demonstrated beneficial medicinal attributes. For example, the pharmaceutical antidiabetes agent, metformin, is a derivative of natural plant products (67) . It has been shown that AMPK activation by pharmacological (AICAR, metformin, and statin) or genetic means (adenoviral overexpression of constitutively active AMPK mutants) significantly mitigated ER stress and SERCA oxidation and improved the endothelium-dependent relaxation in isolated mouse aortae (68) . Kim et al (69) have also shown that metformin blocks palmitate-induced apoptosis and ER stress response in HepG2 liver cells. Recently it has been demonstrated that macelignan (a compound from Myristica fragrans and PPARD/J dual agonist) reduced endoplasmic reticulum (ER) stress in the liver and white adipose tissue of db/db mice as well as in thapsigargin-incubated SKHEP1 and 3T3-L1 cells and improved insulin receptor substrate (IRS)-1 signaling (70) . In an elegant ER stress-activated indicator (ERAI) transgenic mice which expresses green fluorescent protein under ER stress conditions, Yoshiuchi et al (71) demonstrated that pioglitazone treatment suppresses ER stress in the liver and reduced insulin resistance. Tsunekawa et al (72) have demonstrated that reduction of ER stress is one of mechanisms by which pancreatic E-cells are protected by extendin-4, a potent GLP-1 agonist. While extendin-4 prevents lipotoxic E-cell apoptosis by increasing cellular defense mechanisms through the induction of the ER chaperone BiP and the anti-apoptotic protein JunB, it also offers protection from synthetic ER stressors via inactivation of caspase 12 and upregulation of Bcl-2 and XIAP to block mitochondrial apoptosis (73) .
Chemical Chaperones to ameliorate ER stress
Novel classes of agents that increase the folding capacity of the ER (for example, chemical chaperones, inducers of GRP78 and other ER chaperones) and compounds that selectively stimulate ERAD activity could also be envisioned for several chronic diseases in which UPR is pathologically induced. There is an increasing interest in the pharmaceutical industry to design drugs that could reduce or prevent ER stress by reducing the production of mutant or misfolded proteins, increasing the expression of ER chaperones, increasing the stability of proteins, boosting the processing capacity of the ER, etc. Agents in this category include chemical chaperones such as 4-phenyl butyrate (PBA) and tauroursodeoxycholic acid (TUDCA). Both PBA and TUDCA have been shown to regulate ER stress in animals as measured by the reduced phosphorylation of PERK, reduced activation of JNK, and reduced phosphorylation of IRE-1D (74) . In addition, both PBA and TUDCA regulate insulin receptor signaling in animals, as measured by increased tyrosine phosphorylation of insulin receptor, insulin receptor substrate-1 (IRS-1) and increased serine phosphorylation of Akt.
Further preclinical studies of various genes and gene products involved in ER-initiated cell death are needed to fully validate ER stress targets for drug discovery. The development of strategies aimed at promoting proper folding and maturation of mutant proteins and amelioration of ER stress could provide new therapies for a wide spectrum of diseases including diabetes. The fact that small cell permeable molecules can act as either chemical chaperones or pharmacological (ligandmediated) chaperones to rescue mutant protein function has taken us one step further towards this goal. The selectivity of action offered by ligand mediated chaperones might represent a significant advantage over chemical chaperones by allowing tailor-made interventions that are less likely to result in toxic effects. Clinical trials testing the effects of pharmacological chaperones are currently underway; thus, we should know soon whether a new class of drug will be added to our therapeutic arsenal for diabetes and its complications.
